# EpiBiologics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/epibiologics

- Industry: Biotechnology
- Headquarters: San Mateo, US
- Website: www.epibiologics.com
- Total disclosed funding: $160M
- Latest round: Series B (Jan 8, 2026)
- Investors on record: 9

## About

Founded in 2022 and based in California, US, EpiBiologics, Inc. operates as a biotechnology company that focuses on protein breakdown and targeting transmembrane and interfacial proteins. The company is co-founded by Rami Hannoush (CEO) and others. In July 2023, EpiBiologics, Inc. raised USD 23 million in series A funding from new investors Codon Capital, Digitalis Ventures, and Taiho Ventures. In January 2026, EpiBiologics, Inc. raised USD 107 million in series B funding Johnson & Johnson Innovation, GV, Codon Capital, Digitalis Ventures, Mission Biocapital, Polaris Partners, Taiho Ventures, and Vivo Capital.

The company will use the funding to advance its pipeline of bispecific antibodies, move its lead program into first-in-human trials for lung and head and neck cancers, and support programs targeting oncology and immunology.

## Funding rounds

- Series B, Jan 8, 2026, $107M — Polaris Partners, Johnson & Johnson Innovation, Vivo Capital, GV, Mission Biocapital, Digitalis Ventures, Taiho Ventures, Codon Capital
- Series A, Jul 20, 2023, $23M — Digitalis Ventures, Taiho Ventures, Codon Capital
- Series A, Mar 21, 2023, $30M — Polaris Partners, Vivo Capital, GV, Mubadala Capital

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A, Series B
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series A
- Digitalis Ventures (https://capitalatlas.ai/funds/digitalis-ventures) — Series A, Series B
- Taiho Ventures (https://capitalatlas.ai/funds/taiho-ventures) — Series A, Series B
- Codon Capital (https://capitalatlas.ai/funds/codon-capital) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series B
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series B